Deep Track Capital’s Cytokinetics CYTK Stock Holding History

Deep Track Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.6M	Sell	700,000 -674,320	-49%	-$48.4M	0.87%	37
2026 Q1	$90.6M	Sell	1,374,320 -1,962,678	-59%	-$125M	1.48%	21
2025 Q4	$212M	Sell	3,336,998 -963,002	-22%	-$59.9M	3.78%	7
2025 Q3	$236M	Buy	4,300,000 +650,000	+18%	+$26.8M	6.6%	3
2025 Q2	$121M	Buy	3,650,000 +576,147	+19%	+$20M	3.87%	10
2025 Q1	$124M	Buy	3,073,853 +573,853	+23%	+$26.4M	4%	8
2024 Q4	$118M	Buy	2,500,000 +1,870,094	+297%	+$97.1M	4.39%	7
2024 Q3	$33.3M	Buy	629,906 +497,411	+375%	+$27.7M	1.05%	31
2024 Q2	$7.18M	Buy	+132,495	New	+$8M	0.21%	54
2024 Q1	–	Sell	-288,949	Closed	-$24.1M	–	70
2023 Q4	$24.1M	Buy	+288,949	New	+$10.5M	0.81%	44

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deep Track Capital's CYTK Position: Q2 2026 in Review

Deep Track Capital reduced its Cytokinetics (CYTK) stake by 49% in Q2 2026, selling an estimated $48.4M and leaving 700,000 shares worth $59.6M. The position accounts for 0.87% of the portfolio, ranked #37.

Deep Track Capital first reported a position in CYTK in Q4 2023 and has held it in 10 quarters since. The position peaked at $236M in Q3 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Deep Track Capital held 700,000 shares of Cytokinetics worth $59.6M as of Q2 2026.
Deep Track Capital sold 674,320 Cytokinetics shares in Q2 2026, an estimated $48.4M.
Cytokinetics made up 0.87% of Deep Track Capital's portfolio in Q2 2026, its #37 holding.
Deep Track Capital first reported a position in Cytokinetics in Q4 2023 and has held it in 10 quarters since.
Deep Track Capital's Cytokinetics position peaked at $236M in Q3 2025.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.